



IndiTreat[®] mCRC Start

TARGET PATIENTS

The target for the **IndiTreat[®] mCRC Start** test is patients with newly diagnosed metastatic colorectal cancer (synchronous metastases) or previously treated localized disease with new onset of metastases (metachronous metastases). The aim of drug treatment is to downsize metastases to make them operable, or palliative to extend survival and / or improve quality of life.


TREATMENT GUIDELINES

Patients with metastases not suited for primary surgery are offered first line systemic therapy. The chemotherapy options are typically a cytotoxic doublet such as **FOLFOX** or **FOLFIRI** or, in very selected patients the cytotoxic triplet **FOLFOXIRI** or the monotherapy fluorouracil. In practice, most patients are treated with **FOLFOX** or **FOLFIRI** in first line and when the disease progresses, the “opposite” regimen is used in second line.

TREATMENT OUTCOME

The average treatment outcome of **FOLFOX** and **FOLFIRI** in first line is comparable with a response rate of 55%, Progression-Free Survival of 8 months and Overall Survival following a “continuum of care” of nearly 3 years. However, patients respond differently to **FOLFOX** and **FOLFIRI**, and data suggests that getting the right treatment sequence (**FOLFOX** followed by **FOLFIRI** vs. **FOLFIRI** followed by **FOLFOX**) for an individual patient may double survival length compared to getting the opposite sequence. The challenge is that there are no biomarkers to predict this response.

MEDIAN OVERALL SURVIVAL (MONTHS FROM TREATMENT START TO DEATH)




(Clin Cancer Res 2021;27:1174–83)

VALUE OF GUIDED TREATMENT

The unique value of the **IndiTreat® Start** test is that the individual patient response to the different drug regimens is predicted based on tumoroids created from the patient's own tumoral cells. This is of major importance because getting the right therapy as the first step increases the patient's chances that operation becomes possible, or significantly longer Progression-Free and Overall Survivals are achieved.

IndiTreat® mCRC Start – DRUG PANEL	
Ordering Code: 2CX-01-CRC-02	
5-fluorouracil (5FU)	FOLFIRI
FOLFOX	FOLFOXIRI



IndiTreat®
by 2cureX

2cureX

Fruebjergvej 3
2100 Copenhagen
Denmark

Mail: support@2curex.com
www.inditreat.com